Case Firalis

Innovative diagnosis test for Alzheimer’s disease

There is an urgent medical need for a diagnostic tool for Alzheimer’s disease (AD) that is reliable, fast and non-invasive. Firalis SAS hold(s) an exclusive license on an innovative technology for an AD diagnosis test, based on the detection of two complementary biomarkers in red blood cells.

The aim of this project is to further develop the blood AD diagnostic test for routine use in a clinical setting.

A successful grant application and a good match

Catalyze wrote a successful grant application for the project and was able to secure funding from the Eurotransbio program. In addition to that, Catalyze played an important part in finding project partners. It was a challenge to find a partner who could make fluorescent labels, but we managed to attract JPT Peptide Technologies GmbH to the project, which turned out to be a very good match.At the end of this project, a prototype of the novel test for AD disease is available that will enter full clinical validation studies. In addition, directly after this project, specific components of the test will be available on the market as ‘Research Use Only’ products, further promoting research and development in the field of AD.

The project was awarded a grant from the Euro Trans Bio program.

Newsletter

A must-have if you’re interested in getting your business to the next level